Paul Biondi

Paul Biondi is a Managing Partner at Flagship Pioneering and President of Pioneering Medicines, Flagship Pioneering’s in-house drug development unit, dedicated to conceiving and developing a broad portfolio of life-changing treatments for patients built from Flagship’s innovative platforms. In addition to the leadership he provides to Flagship as Managing Partner, Paul also leads therapeutic partnering and business development efforts for the Flagship ecosystem, including driving broad institution-wide Innovation Supply Chain partnerships with biopharma companies to jointly conceive and create innovative products. Current partners include GSK, Novo Nordisk, and Pfizer.

Paul also works with Flagship company CEOs and their teams to achieve the best attainable value for each company, guiding them in their pipeline strategy, product concepts, R&D execution, and partnering approach. He serves on the boards of Flagship-founded companies, including Tessera Technologies (NASDAQ: TSRA) and Valo Health.

Paul joined Flagship following a seventeen-year tenure at Bristol-Myers Squibb (BMS). He served as the Senior Vice President of Strategy and Business Development, where he had enterprise-wide responsibility for establishing and evolving BMS’s strategy, and for pursuing strategic transactions to access external innovation, enhance BMS’s capabilities, and strengthen the company’s portfolio. Prior to this role, Paul held a series of leadership roles within BMS’ R&D organization, overseeing strategy, portfolio, and project management, and clinical and business operations. Paul previously spent nine years at Mercer Management Consulting.

Paul received his MBA from the J.L. Kellogg School of Management at Northwestern University and his B.A. from Dartmouth College.